World's Best Scientists 2026 revealed!

Overview

John W. Park is affiliated with the University of California, San Francisco in the United States. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant emphasis on Oncology and Cancer Research as subfields.

The scientist's work addresses topics related to cancer biology and clinical treatment, including:

  • Cancer Cells and Metastasis
  • Cancer Genomics and Diagnostics
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • Lung Cancer Treatments and Mutations
  • BRCA gene mutations in cancer
  • Bone health and treatments

John W. Park has contributed to several peer-reviewed publications. Some notable recent papers include:

  • Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer, 2020, JAMA Oncology
  • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy, 2020, JNCI Journal of the National Cancer Institute
  • Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab, 2020, Clinical Cancer Research
  • Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid, 2021, npj Breast Cancer
  • A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression, 2020, Journal of Clinical Oncology

Their publications have appeared in the following frequent venues:

  • npj Breast Cancer
  • JAMA Oncology
  • JNCI Journal of the National Cancer Institute
  • Clinical Cancer Research
  • Journal of Clinical Oncology

John W. Park frequently collaborates with other researchers. Regular co-authors include:

  • Hope S. Rugo
  • Mark Jesus M. Magbanua
  • A. Jo Chien
  • Michelle Melisko
  • Laura J. Esserman

Best Publications

  • Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

    Teri N. Kreisl;Lyndon Kim;Kraig Moore;Paul Duic

  • Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

    Dmitri B. Kirpotin;Daryl C. Drummond;Yi Shao;M. Refaat Shalaby

  • Identification of heregulin, a specific activator of p185erbB2.

    William E. Holmes;Mark X. Sliwkowski;Robert W. Akita;William J. Henzel

  • Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

    John W Park;Keelung Hong;Dmitri B Kirpotin;Gail Colbern

  • Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

    Hope S. Rugo;Roy S. Herbst;Glenn Liu;John W. Park

  • The cancer glycocalyx mechanically primes integrin-mediated growth and survival

    Matthew J. Paszek;Christopher C. DuFort;Olivier Rossier;Russell O Bainer

  • STERICALLY STABILIZED ANTI-HER2 IMMUNOLIPOSOMES : DESIGN AND TARGETING TO HUMAN BREAST CANCER CELLS IN VITRO

    Dmitri Kirpotin;John W. Park;Keelung Hong;Samuel Zalipsky

  • Liposome-based drug delivery in breast cancer treatment.

    John W Park

  • Subtype and pathway specific responses to anticancer compounds in breast cancer.

    Laura M. Heiser;Anguraj Sadanandam;Wen-Lin Kuo;Stephen C. Benz

  • Epidermal Growth Factor Receptor–Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs In vivo

    Christoph Mamot;Daryl C. Drummond;Charles O. Noble;Verena Kallab

  • Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells

    Christoph Mamot;Daryl C Drummond;Udo Greiser;Keelung Hong

  • Tumor targeting using anti-her2 immunoliposomes

    J.W. Park;D.B. Kirpotin;K. Hong;R. Shalaby

  • Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

    Daryl C. Drummond;Charles O. Noble;Zexiong Guo;Keelung Hong

  • Development of anti-p185HER2 immunoliposomes for cancer therapy.

    J W Park;K Hong;P Carter;H Asgari

  • Adaptive Randomization of Neratinib in Early Breast Cancer

    John W Park;Minetta C Liu;Douglas Yee;Christina Yau

  • Immunoliposomes that optimize internalization into target cells

    Christopher C. Benz;Demetrios P. Papahadjopoulos;John W. Park;Keelung Hong

  • Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

    Glenn Liu;Hope S. Rugo;George Wilding;Teresa M. McShane

  • Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

    Daryl C. Drummond;Charles O. Noble;Mark E. Hayes;John W. Park

  • Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.

    Kevin C. Weng;Charles O. Noble;Brigitte Papahadjopoulos-Sternberg;Fanqing F. Chen

  • Circulating Tumor Cells

    Mark Jesus M. Magbanua;John W. Park

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Christopher C. Benz
Christopher C. Benz Buck Institute for Research on Aging
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Krystof S. Bankiewicz
Krystof S. Bankiewicz The Ohio State University
James D. Marks
James D. Marks University of California, San Francisco
Christina Yau
Christina Yau University of California, San Francisco
Mitchel S. Berger
Mitchel S. Berger University of California, San Francisco
Andrei Goga
Andrei Goga University of California, San Francisco
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Dan H. Moore
Dan H. Moore University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in healthcare doesn’t have to mean going to medical school. There are a variety of online degrees that can open the door to in-demand roles in the industry, often with flexible and affordable options.

For students interested in healthcare leadership, pursuing one of the cheapest mha programs online can lead to management jobs in hospitals, clinics, and health organizations. If advanced nursing is your goal, many professionals are now choosing the least expensive dnp programs to become nurse practitioners or healthcare policy leaders.

Pharmacy is another growing field, and those looking for advanced practice credentials can explore online pharm d programs designed with working students in mind. Meanwhile, for those interested in technology, administration, and patient data, rhia certification programs online offer pathways to manage the flow of health information in modern systems.

These programs offer new career pathways for those seeking flexibility, affordability, or new roles in the healthcare sector.

Best Scientists Citing John W. Park

Trending Scientists